Shionogi Company Limited

Viiv Healthcare Company

Purdue Pharma L.p.

Hokkaido University

Glaxosmithkline LLC

Yoshiyuki Taoda

Brian Alvin Johns

Takashi Kawasuji

Makoto Kawai

Teruhiko Taishi

Hiroshi Yoshida

Hidenori Mikamiyama

Toshiyuki Akiyama

Kenji Tomita

Naoyuki Suzuki

Jiangchao Yao

R Richard Goehring

Kenji Morimoto

Bin Shao

Naoki Tsuno

Daiki Nagamatsu

John William Frank Whitehead

Minako Mikamiyama

Masayoshi Miyagawa

Akihiko Sato

Akihiro Ishii

Hiroyuki Kai

Tsutomu Iwaki

Yoshinori Tamura

Kenji Takaya

Kouki Fuchino

Kosuke Anan

Chika Takahashi

Yuto Unoh

Yasunori Aoyama

Jason Gordon Weatherhead

Kenji Nakahara

Akira Matsumura

Yuki Tachibana

Hiroyuki Tobinaga

John W F Whitehead

Takeshi Endoh

Shuichi Sugiyama

Masafumi Iwatsu

Shigeru Ando

Richard R Goehring

Kentaro Asahi

Chika Kageyama

Minamo Iwata

Shota Uehara

Yukiko Yamatsu

Michihito Sasaki

Hindenori Mikamiyama

Koji Kasamatsu

Takahiro Suto

Atsuhiro Iimuro

The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; Ris halogen or the like; Rand Rare each independently hydrogen or the like; Ris substituted or unsubstituted alkyl or the like; Ris hydrogen or the like; and n is an integer of 1 to 3.

Polycyclic carbamoylpyridone derivative

The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound. An arenavirus proliferation inhibitor comprising a compound represented by Formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof: (wherein Ris carboxy, or the like: Ais CRor N; Ris a hydrogen atom, halogen, hydroxy, or the like; Ris a hydrogen atom, hydroxy, carboxy, cyano, formyl, alkyl optionally substituted with Substituent group F, or the like; either Aor Ais CRR, and the other is NR, or Ais CRR, and Ais CROR; and R, R, R, R, R, R, and Rare each independently a hydrogen atom, carboxy, cyano, alkyl optionally substituted with Substituent group F, or the like).

Arenavirus growth inhibitor comprising polycyclic carbamoyl pyridone derivative

The present invention provides a compound exhibiting coronavirus 3 CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula: or a pharmaceutically acceptable salt thereof.

Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same

The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound. An arenavirus proliferation inhibitor comprising a compound represented by Formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof: (wherein Ris carboxy, or the like; Ais CRor N; Ris a hydrogen atom, halogen, hydroxy, or the like; Ris a hydrogen atom, hydroxy, carboxy, cyano, formyl, alkyl optionally substituted with Substituent group F, or the like; either Aor Ais CRR, and the other is NR, or Ais CRR, and Ais CRR; and R, R, R, R, R, R, and Rare each independently a hydrogen atom, carboxy, cyano, alkyl optionally substituted with Substituent group F, or the like).

Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative

The present invention provides a compound represented by the following formula (I): wherein, ring A is a substituted or unsubstituted non-aromatic heterocycle; ring C is a benzene ring or the like; Q is a 5-membered aromatic heterocycle or the like; each Ris independently halogen or the like; L is substituted or unsubstituted alkylene; Ris substituted or unsubstituted alkyl or the like; Ris hydrogen or the like; and n is an integer of 1 to 3.

Polycyclic pyridone derivative

Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1',2&#x2032;:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.

Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1',2&#x2032;:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity

The present invention is directed to N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide of the formula: or a pharmaceutically acceptable salt or stereoisomer thereof, and pharmaceutical compositions comprising the same. The present invention has HIV integrase inhibitory activity.

N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity

The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.

Substituted polycyclic carbamoyl pyridone derivative prodrug

This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.

Substituted polycyclic carbamolypyridone derivative

The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

Substituted-quinoxaline-type piperidine compounds and the uses thereof

Substituted polycyclic carbamoylpyridone derivative

The invention is a process for the preparation of a compound of the following formula (I): wherein R is &#x2014;CHO, &#x2014;CH(OH)or &#x2014;CH(OH)(OR); Pis H or a hydroxyl protecting group; Pis H or a carboxy protecting group; Ris H, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted cycloalkyl, etc.; Ris H, halogen or R&#x2014;X&#x2014;NR&#x2014;C(O)&#x2014;; etc. as defined in the specification. The compounds are useful as intermediates in synthesizing compounds having HIV integrase inhibitory activity.

Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates

Growing community of inventors

Osaka, Japan

Yoshiyuki Taoda